Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0006556,
umls-concept:C0012634,
umls-concept:C0017262,
umls-concept:C0017776,
umls-concept:C0017973,
umls-concept:C0035323,
umls-concept:C0035366,
umls-concept:C0127400,
umls-concept:C0185117,
umls-concept:C0205224,
umls-concept:C0221908,
umls-concept:C0243125,
umls-concept:C0348011,
umls-concept:C0699900,
umls-concept:C1533691,
umls-concept:C1704259,
umls-concept:C1705822,
umls-concept:C1705987,
umls-concept:C1947976,
umls-concept:C2911684
|
| pubmed:issue |
5
|
| pubmed:dateCreated |
1990-8-28
|
| pubmed:abstractText |
A beta-glucuronidase mediated pathway for the degradation of glycosaminoglycans is present in the retinal pigment epithelium. The pathway has been defined using ocular tissues and cultured cells from mutant animals having a recessively inherited deficiency of the lysosomal enzyme. In situ, storage products accumulate in secondary lysosomes of the retinal pigment epithelium, the cytoplasm fills with inclusions and the cells hypertrophy; severity of the disease increases with aging. Deficient activity of beta-glucuronidase is present in primary and second passage cultures. Radiolabel studies with 35SO4 show a significant retention of cell layer label by mutant retinal pigment epithelial cells during a 72-hr pulse or 24-hr chase period. The labels is in newly synthesized chondroitin sulfate and heparan sulfate, which are natural substrates for the deficient enzyme. There is no difference from normal in the total radioactivity and electrophoretic profile of the glycosaminoglycans that are synthesized and released into the media. A retroviral vector was used to transfer normal rat beta-glucuronidase cDNA into the mutant cells. The vector treatment results in restoration of enzyme activity and correction of the degradative defect; 35SO4 labeling shows that chondroitin sulfate and heparan sulfate levels return to normal. The vector treatment studies indicate that a single gene defect determines the abnormal beta-glucuronidase mediated pathway in the mutant retinal pigment epithelium.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0014-4835
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
50
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
521-32
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:2164946-Animals,
pubmed-meshheading:2164946-Cells, Cultured,
pubmed-meshheading:2164946-DNA, Viral,
pubmed-meshheading:2164946-Dogs,
pubmed-meshheading:2164946-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:2164946-Glucuronidase,
pubmed-meshheading:2164946-Glycosaminoglycans,
pubmed-meshheading:2164946-Pigment Epithelium of Eye,
pubmed-meshheading:2164946-Retinal Diseases,
pubmed-meshheading:2164946-Simplexvirus,
pubmed-meshheading:2164946-Transfection
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Beta-glucuronidase mediated pathway essential for retinal pigment epithelial degradation of glycosaminoglycans. Disease expression and in vitro disease correction using retroviral mediated cDNA transfer.
|
| pubmed:affiliation |
Scheie Eye Institute, School of Medicine, University of Pennsylvania, Philadelphia 19104-6010.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|